Clinical Trial Update: Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a PD-1–blocking monoclonal antibody in combination with a metabolic modulator for several solid tumors is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Melanoma
• Microsatellite Instability-high Solid Malignant Tumor
• Non-small Cell Lung Cancer
• Urothelial Carcinoma

Snippet

Sponsor: Dan Zandberg | Conditions: Melanoma, NSCLC | Phase 2 | Status: RECRUITING